Evidence map›Paper›PMID 39990220›Full record

ArticleTheranostics2025

First-in-human study of an optimized, potential kit-type, SSTR antagonist

Jingjing Zhang, Lukas Greifenstein, Vivianne Jakobsson, Elcin Zan, Andre Klega, Frank Rösch, Christian Landvogt, Corinna Mueller, Richard P Baum

Abstract read
In one paragraph

Article in Theranostics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Synthesis, preclinical evaluation, and clinical translation of [European journal of nuclear medicine and molecular imaging · 2026
    Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jingjing ZhangDepartment of Diagnostic Radiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
Lukas GreifensteinCuranosticum Wiesbaden-Frankfurt, Center for Advanced Radiomolecular Precision Oncology, Wiesbaden, Germany.
Vivianne JakobssonDepartment of Diagnostic Radiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
Elcin ZanDepartment of Radiology, New York University Langone Medical Center, New York, NY, USA.
Andre KlegaCuranosticum Wiesbaden-Frankfurt, Center for Advanced Radiomolecular Precision Oncology, Wiesbaden, Germany.
Frank RöschDepartment of Chemistry, TRIGA, Johannes Gutenberg University, Mainz, Germany.
Christian LandvogtCuranosticum Wiesbaden-Frankfurt, Center for Advanced Radiomolecular Precision Oncology, Wiesbaden, Germany.
Corinna MuellerCuranosticum Wiesbaden-Frankfurt, Center for Advanced Radiomolecular Precision Oncology, Wiesbaden, Germany.
Richard P BaumCuranosticum Wiesbaden-Frankfurt, Center for Advanced Radiomolecular Precision Oncology, Wiesbaden, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Radiolabeled somatostatin receptor (SSTR) agonists

Indexed as

Gallium RadioisotopesNeuroendocrine TumorsRadiopharmaceuticalsReceptors, SomatostatinAdultAgedFemaleHumansMaleMiddle AgedNeoplasm MetastasisPositron Emission Tomography Computed TomographyTissue DistributionGallium RadioisotopesRadiopharmaceuticalsReceptors, Somatostatin68Ga-DATA5m-LM4first-in-humanneuroendocrine tumors (NETs)PET/CTsomatostatin receptorSSTR antagonist

Identifiers

PMID39990220
PMCPMC11840726

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.